New combo shows promise against tough lymphomas
NCT ID NCT04479267
First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 26 times
Summary
This study tests a new drug combination for people with aggressive types of lymphoma that haven't been treated yet. The treatment adds a targeted drug called polatuzumab vedotin to standard chemotherapy. The goal is to see if this combo can make the cancer disappear completely and stay away, while monitoring for side effects. The study enrolled 8 participants and is no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.